---
title: "Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury"
nct_id: NCT03296761
overall_status: UNKNOWN
sponsor: Jingyuan,Xu
study_type: OBSERVATIONAL
primary_condition: Evaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDS
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03296761.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03296761"
ct_last_update_post_date: 2017-11-01
last_seen_at: "2026-05-12T07:03:10.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury

**NCT ID:** [NCT03296761](https://clinicaltrials.gov/study/NCT03296761)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 70
- **Lead Sponsor:** Jingyuan,Xu
- **Conditions:** Evaluate the Correlation Between the Level of ESM-1 and the Prognosis of the Patients With ARDS
- **Start Date:** 2017-11-01
- **Completion Date:** 2018-02-20
- **CT.gov Last Update:** 2017-11-01

## Brief Summary

To observe the changes of plasma ESM-1 levels in patients with ARDS, and to explore its clinical significance.

## Detailed Description

70 patients who diagnosed as ARDS were included in this study. Then keep blood samples from these patients in the first day, the third day and the seventh day, detect ESM-1 level in plasma by ELISA. Record Severity of illness and survival status of every patient within 28 days. Objective to evaluate the correlation between the level of ESM-1 in plasma and the prognosis of the patients.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Patients admitted to ICU diagnosed of ARDS (Berlin definition）in 48h
2. Patients age between 18 years old and 80 years.

Exclusion Criteria：

1. Pregnant women,
2. Patients with malignant tumor,
3. Immunosuppression or immunocompromised patients.
```

## Arms

- **ESM-1<5ng/ml**
- **ESM-1≥5ng/ml**

## Primary Outcomes

- **mortality** _(time frame: 28-day)_

## Locations (1)

- Nanjing Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.nanjing zhongda hospital, school of medicine, southeast university|nanjing|jiangsu|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03296761.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03296761*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*